Palleiko Benjamin L 4

What Happened
Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals (KALV), was granted 325,000 restricted stock units (RSUs) on January 16, 2026. The grant is recorded as a derivative award with an acquisition price of $0.00 (no cash paid at grant); the Form 4 was filed on January 21, 2026.

Key Details

• Transaction date: January 16, 2026; Form 4 filed January 21, 2026 (5 days after the transaction).
• Transaction type/code: Award/Grant (A); 325,000 RSUs granted at $0.00 (derivative award).
• Shares owned after transaction: not specified in the information provided on the filing.
• Footnote F1: Each RSU represents a contingent right to receive 1 share of common stock upon settlement for no consideration.
• Footnote F2: Vesting: 1/16th of the total RSUs vests on each quarterly anniversary of the vesting commencement date, starting May 22, 2026, contingent on continued service.
• Filing timeliness: The filing was submitted five days after the grant date, later than the typical 2-business-day Form 4 deadline.

Context
RSU grants are a common form of executive compensation and are not an open‑market purchase or sale; they do not convey actual shares until vested/settled. Because the grant lists $0 as the acquisition price, there was no immediate cash outlay by the insider, and no immediate change in freely tradable shares. The vesting schedule (quarterly over four years, given 1/16th per quarter) means the award vests gradually subject to continued service.